Evaluation of CBC in Different Vaccines Types of COVID-19
Main Article Content
Abstract
In December 2019, Wuhan reported its first cases of pneumonia which called coronavirus disease 2019 (COVID-19), a single-stranded RNA virus. COVID-19 vaccine is a safe way to help the immune system build defenses against COVID-19. The immune system relies on various types of cells, such as Lymphocytes, monocytes, macrophages, and other immune cells to fight infections. The aim of the study is to the assessment of blood parameters in different vaccinated groups of COVID-19 vaccines. We collected 100 samples from individuals that vaccinated with AstraZeneca, Sinopharm, and Pfizer vaccines and unvaccinated (infected), which were divided into four groups, each containing 25 samples, and did a CBC test. The study results indicate that different COVID-19 vaccines and natural immunization result in diverse immune responses in males and females. In males, the Sinopharm vaccine stimulates higher white blood cell count (7.11±0.44s) with a significant difference (p<0.05), while the AstraZeneca vaccine triggers greater lymphocyte (LYM%) activation (34.3±0.99) with a significant difference (p<0.05) than others covid19 vaccines. Natural immunization leads to increased monocyte (MON%) levels (8.34±0.69) with a significant difference (p<0.05) compared to covid19 vaccines in which the Sinopharm vaccine (6.96±0.49) shows significantly lower monocyte activation. The Pfizer and Sinopharm vaccines induce higher granulocyte (GRA%) activation (60.34±1.88 and 60.28±1.63, respectively) with a significant difference (p<0.05), while natural immunization (55.87±3.8) shows lower activation compared to covid19 vaccines with a significant difference (p<0.05). While in females, The AstraZeneca, Sinopharm vaccines, and natural immunization (6.1±0.5, 6.89±0.68, and 6.26±0.52, respectively) had the higher white blood cell (WBC) number with no significant difference(p>0.05) among them, while the Pfizer vaccine (5.7±0.36) had the lower WBC with a significant difference (p<0.05). The AstraZeneca vaccine had higher lymphocytes (LYM%) (36.14±1.25) with a significant difference (p<0.05), while the Sinopharm vaccine had significantly lower (29.85±3.62). Natural immunization had a significantly higher MON% (8.11±1.28a) with (p<0.05) compared to covid19 vaccines (with no significant difference among them), while the Sinopharm vaccine showed a higher in both GRA% and GRA number (64.38±3.88 and 4.52±0.57, respectively) with a significant difference (p<0.05). In conclusion, the AstraZeneca vaccine elevated the lymphocytes (LYM%) while natural immunization increased (MON%) in both genders. The study also reveals that males and females exhibit varied immune responses to different COVID-19 vaccines and natural immunization, and these variations may be attributed to vaccine composition, mechanisms of action, immune response variability, and timing of the research.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Austermann, J., Roth, J., & Barczyk-Kahlert, K. (2022). The Good and the Bad: Monocytes’ and Macrophages’ Diverse Functions in Inflammation. Cells, 11(12).
https://doi.org/10.3390/cells11121979
II. Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Di Napoli, R. (2022). Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [Internet].
III. Ekşioğlu-Demiralp, E., Alan, S., Sili, U., Bakan, D., Ocak, İ., Yürekli, R., Alpay, N., Görçin, S., & Yıldız, A. (2022). Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes, and half-dead lymphocytes. Cytometry Part B - Clinical Cytometry, 102(2), 153–167. https://doi.org/10.1002/cyto.b.22042
IV. Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., … Zhong, N. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382(18), 1708–1720.
https://doi.org/10.1056/nejmoa2002032
V. Immune response after COVID-19 vaccination. (n.d.). 19.
VI. Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., Dayarathna, S., Dissanayake, O., Gamalath, N., Ekanayake, D., Jayamali, J., Jayathilaka, D., Dissanayake, M., Jayadas, T. T., Mudunkotuwa, A., … Malavige, G. N. (2022). Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immunity, Inflammation and Disease, 10(6), 1–11. https://doi.org/10.1002/iid3.621
VII. Jiang, F., Deng, L., Zhang, L., Cai, Y., Cheung, C. W., & Xia, Z. (2020). Review of the clinical characteristics o)f coronavirus disease 2019 (COVID-19. Journal of General Internal Medicine, 35(5), 1545–1549.
VIII. Knoll, R., Schultze, J. L., & Schulte-Schrepping, J. (2021). Monocytes and Macrophages in COVID-19. Frontiers in Immunology, 12(July), 1–12. https://doi.org/10.3389/fimmu.2021.720109
IX. Lagadinou, M., Zareifopoulos, N., Gkentzi, D., Sampsonas, F., Kostopoulou, E., Marangos, M., & Solomou, E. (2021). Alterations in lymphocyte subsets and monocytes in patients diagnosed with SARS-CoV-2 pneumonia: A mini-review of the literature. European Review for Medical and Pharmacological Sciences, 25(15), 057–5062. https://doi.org/10.26355/eurrev_202108_26463
X. Mart, D., Aguirre-sampieri, S., Sampieri, A., & Vaca, L. (2021). SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. 12(July).
https://doi.org/10.3389/fimmu.2021.701501
XI. Mittal, A., Manjunath, K., Ranjan, R. K., Kaushik, S., Kumar, S., & Verma, V. (2020). COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathogens, 16(8), e1008762. https://doi.org/10.1371/journal.ppat.1008762
XII. Özdemir, Ö. (2020). Coronavirus Disease 2019 (COVID-19): Diagnosis and Management (narrative review). Erciyes Medical Journal. https://doi.org/10.14744/etd.2020.99836
XIII. Rajamanickam, A., Pavan Kumar, N., Nancy P, A., Selvaraj, N., Munisankar, S., Mariam Renji, R., V, V., Murhekar, M., Wesley Vivian Thangaraj, J., Santhosh Kumar, M., Girish Kumar, C., Bhatnagar, T., Ponnaiah, M., Sabarinathan, R., Saravanakumar, V., & Babu, S. (2022). Dynamic Changes in Neutrophil Counts and Neutrophil Granular Protein Levels in Convalescent COVID-19 Patients. Archives of Clinical and Biomedical Research, 06(02), 378–389.
https://doi.org/10.26502/acbr.50170253
XIV. Sarker, P., Akhtar, E., Kuddusi, R. U., Alam, M. M., Haq, M. A., Hosen, M. B., Chanda, B. C., Haque, F., Alam, M., Razzaque, A., Rahman, M., Ahmed, F., Kibria, M. G., Islam, M. Z., Ahmed, S., & Raqib, R. (2022). Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population. Vaccines, 10(9), 1–12. https://doi.org/10.3390/vaccines10091498
XV. Sayahinouri1, M., Firouz, S. M., Sadrabadi3, A. E., Masoudnia5, M., Abdolahi5, M., Jafarzadeh, F., Nouripour, M., Mirzazadeh, S., Zangeneh, N., Jalili, A., & Aghdami, N. (2023). Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics. BioImpacts, 149–166. https://doi.org/10.15171/bi.2014.008
XVI. Sharma, B. R., & Ravindra, P. V. (2022). Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. 648–664.
https://doi.org/10.37349/ei.2022.00074
XVII. Sotomayor, F., Corbacho, J. M., Valiente, A., Benítez, Y., & Viera, T. (2020). Aspectos generales sobre la estructura del coronavirus del síndrome respiratorio agudo grave 2 (SARS-CoV-2). Revista Cubana de Investigaciones Biomédicas, 30(3), 3–10. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002020000300025
XVIII. Understanding COVID-19 Vaccines. (2021).
XIX. Yu, C., Littleton, S., Giroux, N. S., Mathew, R., Ding, S., Kalnitsky, J., Yang, Y., Petzold, E., Chung, H. A., Rivera, G. O., Rotstein, T., Xi, R., Ko, E. R., Tsalik, E. L., Sempowski, G. D., Denny, T. N., Burke, T. W., McClain, M. T., Woods, C. W., … Saban, D. R. (2021). Mucosal-associated invariant T-cell responses differ by sex in COVID-19. Med, 2(6), 755-772.e5.
https://doi.org/10.1016/j.medj.2021.04.008
XX. Zepeda-cervantes, J., Mart, D., Ram, O., Tecalco-cruz, Á. C., Alavez-p, S., Vaca, L., & Sarmiento-silva, R. E. (2022). Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19.